7UE1 image
Entry Detail
PDB ID:
7UE1
Keywords:
Title:
HIV-1 Integrase Catalytic Core Domain Mutant (KGD) in Complex with Inhibitor GRL-142
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2022-03-21
Release Date:
2023-03-22
Method Details:
Experimental Method:
Resolution:
3.00 Å
R-Value Free:
0.31
R-Value Work:
0.22
R-Value Observed:
0.22
Space Group:
I 4 2 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Integrase
Chain IDs:A, B
Chain Length:166
Number of Molecules:2
Biological Source:Human immunodeficiency virus 1
Primary Citation
GRL-142 binds to and impairs HIV-1 integrase nuclear localization signal and potently suppresses highly INSTI-resistant HIV-1 variants.
Sci Adv 9 eadg2955 eadg2955 (2023)
PMID: 37436982 DOI: 10.1126/sciadv.adg2955

Abstact

Nuclear localization signal (NLS) of HIV-1 integrase (IN) is implicated in nuclear import of HIV-1 preintegration complex (PIC). Here, we established a multiclass drug-resistant HIV-1 variant (HIVKGD) by consecutively exposing an HIV-1 variant to various antiretroviral agents including IN strand transfer inhibitors (INSTIs). HIVKGD was extremely susceptible to a previously reported HIV-1 protease inhibitor, GRL-142, with IC50 of 130 femtomolar. When cells were exposed to HIVKGD IN-containing recombinant HIV in the presence of GRL-142, significant decrease of unintegrated 2-LTR circular cDNA was observed, suggesting that nuclear import of PIC was severely compromised by GRL-142. X-ray crystallographic analyses revealed that GRL-142 interacts with NLS's putative sequence (DQAEHLK) and sterically blocks the nuclear transport of GRL-142-bound HIVKGD's PIC. Highly INSTI-resistant HIV-1 variants isolated from heavily INSTI-experienced patients proved to be susceptible to GRL-142, suggesting that NLS-targeting agents would serve as salvage therapy agents for highly INSTI-resistant variant-harboring individuals. The data should offer a new modality to block HIV-1 infectivity and replication and shed light on developing NLS inhibitors for AIDS therapy.

Legend

Protein

Chemical

Disease

Primary Citation of related structures